THE-BRAIN-FORUM
7.4.2016 11:11:51 CEST | Business Wire | Press release
The Brain Forum brings together top scientists and entrepreneurs from the world’s biggest brain initiatives. The event will run in collaboration with EPFL on 26 and 27 May at the SwissTech Convention Center in Lausanne, Switzerland.
Launched in 2013, The Brain Forum plays an important role in the progression of brain research by connecting researchers, engineers, healthcare professionals, entrepreneurs, investors, funding agencies and policy makers. In so doing, The Brain Forum helps to accelerate our understanding of the brain by translating science from bench to business, thus making laboratory innovations available to all.
Dr. Jamil El-Imad, CEO of The Brain Forum, comments: “We want to include anyone with an interest in the brain. We hope that our different but complementary experience and perspectives can help to overcome the biggest challenges of this era. You can’t build the future based on present assumptions so we need to develop our thinking and be open to spontaneous opportunities that may lead to the necessary serendipity for innovation.”
The Brain Forum has proven a great success in previous years. This year the main objectives are to enhance the attendance of the international community, to promote awareness of brain science at a global level and to stimulate worldwide, unified efforts to tackle one of the biggest healthcare challenges of this century. The event features an impressive line-up of world-renowned experts who promise to give fascinating insights into cutting-edge research, advancements in our understanding of the brain and the impact of that knowledge. International brain initiatives and regulatory bodies from the EU, USA, Japan and China will share how they are working towards improving brain research. Google will host a special session on ‘Lessons from practical machine intelligence’ followed by UBS on ‘The Workforce of the Future,’ while the popular start-up competition returns offering opportunities for start-ups to pitch to investors looking to invest in the solutions of the future.
The Brain Forum was created because scientific exploration of the brain is fundamental for tackling the challenges of the 21st century. As more and more people are affected by neurological and psychiatric conditions, there is increasing awareness of the importance of brain research to healthcare and technology. WHO recently concluded that brain disorders account for 35 per cent of the burden of all diseases in Europe and will become the major medical need of this century. In 2010, the European Brain Council published a report demonstrating that brain disorders cost Europe EUR 800 billion in 2010 – more than cardiovascular disease, cancer and diabetes combined.
Dr. El-Imad adds: “The future is both terrific and terrifying. Our aging populations are increasing the incidence and burden of many neurological and psychiatric diseases presenting huge challenges for healthcare and society, while artificial intelligence will presage a new industrial revolution, altering the workforce of the future and shifting further the balance of humans vs. machines. Technology and science will allow us to do things that we never imagined possible, but we as a society need to be prepared to deal with the consequences – good and bad – of our rapidly changing future.”
To participate - and mould the future of brain science – register at:
www.thebrainforum.org
*Source: ME NewsWire
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005582/en/
Contact:
Headline office
The Brain Forum
Christophe Tournier,
press office, +412-1517-6717
thebrainforum@farner.ch
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IAS Launches IAS Total TV Solutions Giving Marketers ‘Linear-like’ Transparency for Connected TV27.4.2026 14:30:00 CEST | Press release
‘IAS Total TV’ unlocks show, genre and rating transparency measurement across Disney, NBCUniversal, Paramount and Prime Video, plus multiple opted-in publishers using Publica enabling advertisers to enhance brand suitability while increasing campaign outcomes Integral Ad Science (IAS) today announced ‘IAS Total TV’, a new comprehensive suite of Connected TV (CTV) solutions designed specifically to bring ‘linear-like’ transparency to streaming TV. IAS Total TV can provide marketers with genre, rating, language, show and program-level data in aggregate from Disney, NBCUniversal, Paramount and Prime Video, in addition to multiple opted-in publishers using Publica. IAS Total TV integrates content insights, media quality, supply path and outcomes into a unified view within the IAS Signal user interface (UI). Advertisers can determine when and how they want their advertising to run alongside CTV content, ensuring brand-related and brand suitable environments. “As advertisers continue to doub
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
